User login
SAN ANTONIO – Prophylactic beta-blockade with bisoprolol during adjuvant trastuzumab therapy for HER2-positive breast cancer prevented trastuzumab-induced decline in left ventricular ejection fraction in a randomized trial.
In an interview at the San Antonio Breast Cancer Symposium, Dr. Edie Pituskin of the University of Alberta, Edmonton, explained why the double-blind, placebo-controlled MANTICORE trial may change clinical practice.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
SAN ANTONIO – Prophylactic beta-blockade with bisoprolol during adjuvant trastuzumab therapy for HER2-positive breast cancer prevented trastuzumab-induced decline in left ventricular ejection fraction in a randomized trial.
In an interview at the San Antonio Breast Cancer Symposium, Dr. Edie Pituskin of the University of Alberta, Edmonton, explained why the double-blind, placebo-controlled MANTICORE trial may change clinical practice.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
SAN ANTONIO – Prophylactic beta-blockade with bisoprolol during adjuvant trastuzumab therapy for HER2-positive breast cancer prevented trastuzumab-induced decline in left ventricular ejection fraction in a randomized trial.
In an interview at the San Antonio Breast Cancer Symposium, Dr. Edie Pituskin of the University of Alberta, Edmonton, explained why the double-blind, placebo-controlled MANTICORE trial may change clinical practice.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
AT SABCS 2015
